{"id":6918,"date":"2021-03-10T14:01:26","date_gmt":"2021-03-10T14:01:26","guid":{"rendered":"https:\/\/oncopeptides.com\/investors\/aktien\/nyemissioner\/nyemission-2021\/"},"modified":"2026-03-19T15:44:06","modified_gmt":"2026-03-19T15:44:06","slug":"nyemission-2021","status":"publish","type":"investors","link":"https:\/\/oncopeptides.com\/sv\/investerare\/aktien\/nyemissioner\/nyemission-2021\/","title":{"rendered":"Nyemission 2021"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"6918\" class=\"elementor elementor-6918 elementor-6783\" data-elementor-post-type=\"investors\">\n\t\t\t\t<style>\n                .elementor-element-d7b3a0d{\n                --padding-top: var(--webien-padding-top-none);\n                --padding-right: var(--webien-padding-right-none);\n                --padding-bottom: var(--webien-padding-bottom-none);\n                --padding-left: var(--webien-padding-left-none);\n                }\n            <\/style><div class=\"webien-container-padding-none elementor-element elementor-element-d7b3a0d e-flex e-con-boxed e-con e-parent\" data-id=\"d7b3a0d\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<style>\n                .elementor-element-9b7b209{\n                --padding-top: var(--webien-padding-top-none);\n                --padding-right: var(--webien-padding-right-none);\n                --padding-bottom: var(--webien-padding-bottom-none);\n                --padding-left: var(--webien-padding-left-none);\n                }\n            <\/style><div class=\"webien-container-padding-none elementor-element elementor-element-9b7b209 e-con-full haus-2-1 e-flex e-con e-child\" data-id=\"9b7b209\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-cd7d205 elementor-widget elementor-widget-heading\" data-id=\"cd7d205\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h1 class=\"elementor-heading-title elementor-size-default\">Nyemission<br><span style=\"color: var(--color-orange)\">2021<\/span><\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-022026a dotted-divider elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"022026a\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"divider.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t<style>\n                .elementor-element-fd88205{\n                --padding-top: var(--webien-padding-top-none);\n                --padding-right: var(--webien-padding-right-none);\n                --padding-bottom: var(--webien-padding-bottom-none);\n                --padding-left: var(--webien-padding-left-none);\n                }\n            <\/style><div class=\"webien-container-padding-none elementor-element elementor-element-fd88205 e-con-full e-flex e-con e-child\" data-id=\"fd88205\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-885a52e elementor-widget elementor-widget-text-editor\" data-id=\"885a52e\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<h2>Oncopeptides har genomf\u00f6rt en riktad nyemission som tillf\u00f6r bolaget cirka 1 106 miljoner SEK (130 miljoner USD)<\/h2>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-edc1d8d elementor-widget elementor-widget-text-editor\" data-id=\"edc1d8d\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>10 mars 2021 \u2013 Regulatoriskt pressmeddelande<\/p><p>Oncopeptides AB (publ) meddelar att bolaget framg\u00e5ngsrikt har genomf\u00f6rt en riktad nyemission som tillf\u00f6r cirka 1 106 miljoner SEK i bruttolikvid.<\/p><p>Styrelsen f\u00f6r Oncopeptides har, med st\u00f6d av emissionsbemyndigandet fr\u00e5n \u00e5rsst\u00e4mman den 26 maj 2020 och i enlighet med vad som indikerades i bolagets pressmeddelande den 9 mars 2021, beslutat om en riktad nyemission av 7 000 000 nya aktier till en teckningskurs om 158 SEK per aktie (den \u201dRiktade Nyemissionen\u201d), vilket inneb\u00e4r att bolaget tillf\u00f6rs en bruttolikvid om cirka 1 106 miljoner SEK (cirka 130 miljoner USD).<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-844a57b elementor-widget elementor-widget-button\" data-id=\"844a57b\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"https:\/\/oncopeptides.com\/sv\/pressmeddelanden\/oncopeptides-ab-oncopeptides-har-genomfort-en-riktad-nyemission-om-cirka-1-106-miljoner-kronor-130-miljoner-usd\/\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">L\u00e4s pressmeddelandet<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-bcc0bb8 dotted-divider elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"bcc0bb8\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"divider.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t<style>\n                .elementor-element-dcfe7ee{\n                --padding-top: var(--webien-padding-top-none);\n                --padding-right: var(--webien-padding-right-none);\n                --padding-bottom: var(--webien-padding-bottom-none);\n                --padding-left: var(--webien-padding-left-none);\n                }\n            <\/style><div class=\"webien-container-padding-none elementor-element elementor-element-dcfe7ee e-con-full e-flex e-con e-child\" data-id=\"dcfe7ee\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-e2905cf elementor-widget elementor-widget-text-editor\" data-id=\"e2905cf\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<h2>Oncopeptides avser att genomf\u00f6ra en riktad nyemission<\/h2>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-6f1e632 elementor-widget elementor-widget-text-editor\" data-id=\"6f1e632\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>9 mars 2021 \u2013 Regulatoriskt pressmeddelande<\/p><p>Oncopeptides AB (publ) offentligg\u00f6r sin avsikt att genomf\u00f6ra en nyemission av aktier riktad till svenska och internationella institutionella investerare (den \u201dRiktade Nyemissionen\u201d). Bolaget har anlitat Carnegie, Cowen, DNB Markets, JP Morgan och Kempen &amp; Co som Joint Bookrunners (\u201dJoint Bookrunners\u201d) i samband med den Riktade Nyemissionen. <\/p><p>Teckningskursen och det totala antalet nya aktier i den Riktade Nyemissionen kommer att fastst\u00e4llas genom ett accelererat bookbuilding-f\u00f6rfarande (\u201dBookbuilding\u201d). Avsikten \u00e4r att antalet nyemitterade aktier ska uppg\u00e5 till cirka 10 procent av det totala antalet aktier i bolaget. Bookbuilding-f\u00f6rfarandet p\u00e5b\u00f6rjas omedelbart efter detta offentligg\u00f6rande.  <\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-a840a7c elementor-widget elementor-widget-button\" data-id=\"a840a7c\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"https:\/\/oncopeptides.com\/sv\/pressmeddelanden\/oncopeptides-ab-oncopeptides-avser-att-genomfora-en-riktad-nyemission\/\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">L\u00e4s pressmeddelandet<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"featured_media":0,"parent":5698,"menu_order":0,"template":"","meta":{"_acf_changed":false},"protected-content":[341],"class_list":["post-6918","investors","type-investors","status-publish","hentry","protected-content-show-disclaimer"],"acf":[],"_links":{"self":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/investors\/6918","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/investors"}],"about":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/types\/investors"}],"version-history":[{"count":1,"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/investors\/6918\/revisions"}],"predecessor-version":[{"id":6919,"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/investors\/6918\/revisions\/6919"}],"up":[{"embeddable":true,"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/investors\/5698"}],"wp:attachment":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/media?parent=6918"}],"wp:term":[{"taxonomy":"protected-content","embeddable":true,"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/protected-content?post=6918"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}